GlassScriptPhysician profile
Paul S Larson
NPI 1013005321
$95,541.79
in general payments reported to CMS, 2019-2025
11 companies · $4,354 in 2025
The $4,354 reported for 2025 was more than what 79% of Neurological Surgery providers received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16K · 2020: $6,178 · 2021: $17K · 2022: $25K · 2023: $17K · 2024: $11K · 2025: $4,354.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $13K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $12K · Food and Beverage: $3,923 · Travel and Lodging: $3,309.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $12,845.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $11,878.75 |
| Food and Beverage | $3,923.17 |
| Travel and Lodging | $3,309.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Clearpoint Neuro, INC. | $30,268.91 | 2022-2025 | Clearpoint |
| Boston Scientific Corporation | $19,561.97 | 2019-2025 | General - Dbs, Wavewriter Alpha Prime 16 |
| Medtronic, INC. | $13,883.24 | 2021-2025 | Percept PC Brainsense, Sensight, Inceptiv |
| Neurocrine Biosciences, INC. | $9,555.59 | 2019 | |
| Glaxosmithkline, LLC. | $8,970.00 | 2019-2025 | |
| Abbott Laboratories | $7,475.04 | 2020-2024 | Infinity |
| Medtronic USA, INC. | $2,796.68 | 2019-2020 | |
| Biogen, INC. | $1,695.00 | 2021 | |
| Sunovion Pharmaceuticals INC. | $1,210.04 | 2022 | |
| Stryker Corporation | $102.86 | 2022-2025 | Na, Duramatrix |
| Depuy Synthes Sales INC. | $22.46 | 2025 | Symphony, Trialtis, Teligen |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Larson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.